Alkermes Remains Committed to Oncology Innovation

Alkermes Remains Committed to Oncology Innovation

Tuesday, June 21, 2022 - 12:15pm

CAMPAIGN: Alkermes Medicines & Focus: Cancer

CONTENT: Blog

On the heels of ASCO22, we remain committed to innovating in the oncology space, particularly for cancers with high unmet needs, like platinum-resistant ovarian cancer. Thomas Herzog, M.D. and Craig Hopkinson M.D. share their insights on how our actively recruiting ARTISTRY-7 clinical trial in platinum-resistant ovarian cancer aspires to address these needs: https://bit.ly/3azbAjw